Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorne Albrecht

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Drugs in Dermatology : JDD|February 4, 2021
Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis SurveyMelinda Gooderham, Kim Papp, Lorne Albrecht, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm<sup>2</sup> on the chest: A phase 3 randomized controlled trialC William Hanke, Lorne Albrecht, Torsten Skov, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic DermatitisGurbir Dhadwal, Lorne Albrecht, Robert Gniadecki, et al.
Journal of Cutaneous Medicine and Surgery|December 29, 2011
Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendationsLorne Albrecht, Marc Bourcier, John Ashkenas, et al.
Dermatology and Therapy|December 23, 2022
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE RegistryMelinda Gooderham, Kim A Papp, Charles Lynde, et al.
Journal of the American Academy of Dermatology|August 3, 2021
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialLinda Stein Gold, Kim Papp, David Pariser, et al.
BMC Dermatology|June 23, 2019
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin AmericaKim A Papp, Melinda Gooderham, Jennifer Beecker, et al.
Journal of Cutaneous Medicine and Surgery|September 18, 2025
Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special PopulationsIrina Turchin, Lorne Albrecht, Sameh Hanna, et al.
Journal of Cutaneous Medicine and Surgery|September 18, 2025
Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and PathophysiologyIrina Turchin, Lorne Albrecht, Sameh Hanna, et al.
Journal of Cutaneous Medicine and Surgery|September 18, 2025
Current Understanding of Seborrheic Dermatitis: Treatment OptionsIrina Turchin, Lorne Albrecht, Sameh Hanna, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Drugs in Dermatology : JDD|February 4, 2021
Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis SurveyMelinda Gooderham, Kim Papp, Lorne Albrecht, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm<sup>2</sup> on the chest: A phase 3 randomized controlled trialC William Hanke, Lorne Albrecht, Torsten Skov, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic DermatitisGurbir Dhadwal, Lorne Albrecht, Robert Gniadecki, et al.
Journal of Cutaneous Medicine and Surgery|December 29, 2011
Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendationsLorne Albrecht, Marc Bourcier, John Ashkenas, et al.
Dermatology and Therapy|December 23, 2022
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE RegistryMelinda Gooderham, Kim A Papp, Charles Lynde, et al.
Journal of the American Academy of Dermatology|August 3, 2021
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialLinda Stein Gold, Kim Papp, David Pariser, et al.
BMC Dermatology|June 23, 2019
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin AmericaKim A Papp, Melinda Gooderham, Jennifer Beecker, et al.
Journal of Cutaneous Medicine and Surgery|September 18, 2025
Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special PopulationsIrina Turchin, Lorne Albrecht, Sameh Hanna, et al.
Journal of Cutaneous Medicine and Surgery|September 18, 2025
Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and PathophysiologyIrina Turchin, Lorne Albrecht, Sameh Hanna, et al.
Journal of Cutaneous Medicine and Surgery|September 18, 2025
Current Understanding of Seborrheic Dermatitis: Treatment OptionsIrina Turchin, Lorne Albrecht, Sameh Hanna, et al.
Pageof 2